Anavex Life Sciences Corp (AVXL)

[shoeman6]

I wouldnt be surprised if they took a MMSE score at week 5. Remember, one of the major criticisms levied against the prelim Part A data was that Anavex was simply correlating P300 amplitude to MMSE change. I'm sure the researchers were curious themselves (given the significant P300 4x amplitude increase vs. donzepil) what the MMSE was at that time. This wasn't a primary endpoint, but still, wouldn't you want to know given the huge potential increase in efficacy?

I don't think you can read much more into the sentence than that. My guess is 5 weeks was simply an additional MMSE added due to the unexpected P300 results.

Who knows if MMSE with 273 was better, "on average" than donzepil, we will see over the weekend. My hunch is yes, although it seems odd to me why it is not mentioned. Thus spawns my theory that perhaps the temporal effects of donzepil on indicators were modified as opposed to the amplitude.

http://www.anavex.com/files/Anavex_Presentation_Fall_2015+.pdf

Take a look at their chart on page 21. 1 month with 273 seems to be close in P300 change % to 6 months on donzepil. This is pure speculation but increased rate of activity is a clear possibility. What would be left to be discovered is whether or not these levels are then sustained for longer than donzepil, thus prompting the sentence: The current results seem to justify a prospective comparison with current standard of care in a larger clinical trial study.

I am more than likely incorrect. We all are trying to make the best out of incomplete information.

The biggest take aways are:

1. The drug was safe. (more important than some might think)

2. The researchers believe the drug 273 has shown enough promise to justify additional trials.

3. The drug 273 showed clinical improvements in several indicators.

These facts alone should prompt increased pps. There is a lot of potential and a lot of risk. But that's what sets these stocks apart from others. GLTA